The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

被引:1
|
作者
Lv, Qiong [1 ,2 ]
Zhao, Huashan [2 ,3 ,4 ,5 ]
机构
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Electrocardiogram, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, Luoyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
[5] Henan Univ Sci & Technol, Coll Clin Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
关键词
Association; MI; mASLD; risk factors; FATTY LIVER; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MANAGEMENT; ELEVATION; MORTALITY;
D O I
10.1080/07853890.2024.2306192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis to determine the relationship between MASLD and MI risk.Methods PubMed, MEDLINE, Embase, Web of Science, CNKI, CBM, VIP, and WanFang databases were searched, and the DerSimonian Laird method was used to obtain hazard ratios (HRs) for binary variables to assess the correlation between MASLD and MI risk. Subgroup analyses for the study region, MASLD diagnosis, quality score, study design, and follow-up time were conducted simultaneously for the selected studies retrieved from the time of database establishment to March 2022. All study procedures were independently conducted by two investigators.Results The final analysis included seven articles, including eight prospective and two retrospective cohort studies. The MI risk was higher among MASLD patients than among non-MASLD patients (HR = 1.26; 95% CI: 1.08-1.47, p = 0.003). The results of the subgroup analysis of the study region revealed an association of MASLD with MI risk among Americans and Asians, but not in Europeans. Subgroup analyses of MASLD diagnosis showed that ultrasonography and other (fatty liver index[FLI] and computed tomography [CT)]) diagnostic methods, but not international classification of disease (ICD), increased the risk of MI. Subgroup analysis of the study design demonstrated a stronger relationship between MASLD and MI in retrospective studies but not in prospective studies. Subgroup analysis based on the follow-up duration revealed the association of MASLD with MI risk in cases with < 3 years of follow-up but not with >= 3 years of follow-up.Conclusion MASLD increases the risk of MI, independent of traditional risk factors.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    [J]. ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [2] The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Li, Xiaoyan
    He, Jie
    Sun, Qiuhua
    [J]. CLINICAL NUTRITION, 2024, 43 (09) : 2005 - 2016
  • [3] Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis
    Mantovani, Alessandro
    Morandin, Riccardo
    Fiorio, Veronica
    Lando, Maria Giovanna
    Petta, Salvatore
    Ferraro, Pietro Manuel
    Targher, Giovanni
    [J]. INTERNAL AND EMERGENCY MEDICINE, 2024,
  • [4] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    [J]. BMC PUBLIC HEALTH, 2024, 24 (01)
  • [5] Effectiveness of Bariatric Surgeries for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
    AlRumaih, Abdullah Sulaiman
    Alzelfawi, Lama Abdullah
    Alotaibi, Ghadah Khalid
    Aldayel, Osamah AbdulAziz
    Almutairi, Abdulrahman Khazzam
    Alnowaimi, Rosana Tariq
    Alshahrani, Mubarak Mohammed
    Alsharif, Rifal Sami
    Almadani, Sarah Nabil
    [J]. SURGERIES, 2024, 5 (03): : 486 - 498
  • [6] Prognostic value of liver stiffness in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Mu, Yijun
    Peng, Cheng
    Chang, Huijun
    Wang, Shaotong
    Zuo, Xiuli
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (08) : 416 - 422
  • [7] Electrocardiographic abnormalities in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
    Dimala, Christian Akem
    Nso, Nso
    Wasserlauf, Jeremiah
    Njei, Basile
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)
  • [8] Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
    Zhang, Yi
    Zhou, Ben-Gang
    Zhan, Ji-Dong
    Du, Bin-Bin
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [9] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review
    Chan, Wah-Kheong
    Chuah, Kee-Huat
    Rajaram, Ruveena Bhavani
    Lim, Lee-Ling
    Ratnasingam, Jeyakantha
    Vethakkan, Shireene Ratna
    [J]. JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (03) : 197 - 213
  • [10] Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease
    Jamalinia, Mohamad
    Zare, Fatemeh
    Noorizadeh, Kiarash
    Lankarani, Kamran Bagheri
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (04) : 445 - 458